Das Klinikum

Prof. Dr. Helmut Salih

Prof. Dr. Helmut Salih

Ärztlicher Direktor

W3 Professor für Translationale Immunologie, Eberhard Karls Universität Tübingen
Leiter der klinischen Kooperationseinheit Translationale Immunologie im Deutschen Konsortium für Translationale Krebsforschung (DKTK) am DKFZ
Facharzt für Innere Medizin, Hämatologie/Onkologie

Kontakt

Telefonnummer: 07071 29-83275

Faxnummer: 07071 29 -4391

E-Mail-Adresse: helmut.salih@med.uni-tuebingen.de

Klinik / Institut / Zentrum

  • Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Mbarga M, Wang H, Schaefer T, Tandler C, Falcone M, Nievergall E, Dörfel D, Passweg JR, Lutz C, Schwaller J, Zeiser R, Blazar BR, Caligiuri MA, Dirnhofer S, Lundberg P, Kanz L, Quintanilla-Martinez L, Steinle A, Trumpp A, Salih HR*, Lengerke C: Absence of NKG2D ligands defines human leukaemia stem cells and mediates their immune evasion. Nature, accepted* Corresponding and shared senior author
  • Nuebling T, Schumacher CE, Hofmann M, Hagelstein I, Schmiedel BJ, Maurer S, Federmann B, Rothfelder K, Roerden M, Dörfel D, Schneider P, Jung G, Salih HR: The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia.Cancer Immunol Res. 6(2):209-21
  • Koerner SP, André MC, Leibold JS, Kousis PC, Kübler A, Pal M, Haen SP, Bühring HJ, Grosse-Hovest L, Jung G and Salih HR. 2017. An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia.Leukemia 31:459-69
  • Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Specchia G, Efficace F, Sborgia M, Di Bona, E, Breccia M, Cairoli R, Rambaldi A, Melillo L, La Nasa G Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F: Improved Outcomes with Retinoic Acid and Arsenic Trioxide Compared to Retinoic Acid and Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia. Final Results of the Italian-German APL0406 Trial.J Clin Oncol. 35(6):605-12
  • Wild J, Schmiedel BJ, Maurer A, Raab S, Prokop L, Stevanović S, Dörfel D, Schneider P and Salih HR. 2015. Neutralization of NK cell-derived B cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.Leukemia 29:1676-83
  • Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Döhner H, Ehninger G, Schlenk* RF and Platzbecker* U. 2013. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia.N Engl J Med. 369:111-21
  • Placke T, Örgel M, Schaller M, Jung G, Rammensee HG, Kopp HG and Salih HR. 2012. Platelet-derived MHC Class I confers a pseudo-normal phenotype to cancer cells that subverts the anti-tumor reactivity of natural killer immune cells.Cancer Res. 72:440-8
  • Baessler T, Charton JE, Schmiedel BJ, Grünebach F, Krusch, M, Wacker, A, Rammensee H-G, Salih HR: CD137 Ligand Mediates Opposite Effects in Human and Mouse NK Cells and impairs NK cell reactivity against Human Acute Myeloid Leukemia cells.Blood. 115:3058-69
  • Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG and Steinle A. 2003. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.Blood 102:1389-96
  • Salih HR, Rammensee HG, Steinle A: Cutting Edge: Down-regulation of MICA on human tumors by proteolytic shedding.J Immunol 169:4098-102
  • Publikationen